194 related articles for article (PubMed ID: 3498743)
21. Rapid decompression of anterior intracranial visual pathways with bromocriptine.
Grimson BS; Bowman ZL
Arch Ophthalmol; 1983 Apr; 101(4):604-6. PubMed ID: 6838419
[TBL] [Abstract][Full Text] [Related]
22. Bromocriptine treatment of pituitary adenomas.
Baskin DS; Wilson CB
Neurosurgery; 1981 Jun; 8(6):741-4. PubMed ID: 7279165
[No Abstract] [Full Text] [Related]
23. Temozolomide retreatment in a recurrent prolactin-secreting pituitary adenoma: Hormonal and radiographic response.
Strowd RE; Salvatori R; Laterra JJ
J Oncol Pharm Pract; 2016 Jun; 22(3):517-22. PubMed ID: 25616657
[TBL] [Abstract][Full Text] [Related]
24. Effects of bromocriptine on prolactin-secreting pituitary adenomas. Mechanism of reduction in tumor size evaluated by light and electron microscopic, immunohistochemical, and morphometric analysis.
Mori H; Mori S; Saitoh Y; Arita N; Aono T; Uozumi T; Mogami H; Matsumoto K
Cancer; 1985 Jul; 56(2):230-8. PubMed ID: 4005795
[TBL] [Abstract][Full Text] [Related]
25. Hyperprolactinemic response after bromocriptine withdrawal in women with prolactin-secreting pituitary tumors.
Maxson WS; Dudzinski M; Handwerger SH; Hammond CB
Fertil Steril; 1984 Feb; 41(2):218-23. PubMed ID: 6698215
[TBL] [Abstract][Full Text] [Related]
26. Invasive mixed growth hormone/prolactin secreting pituitary tumour: complete shrinking by octreotide and bromocriptine, and lack of tumour growth relapse 20 months after octreotide withdrawal.
Sadoul JL; Thyss A; Freychet P
Acta Endocrinol (Copenh); 1992 Feb; 126(2):179-83. PubMed ID: 1543025
[TBL] [Abstract][Full Text] [Related]
27. Effect of tamoxifen administration on prolactin release by invasive prolactin-secreting pituitary adenomas.
Lamberts SW; Verleun T; Oosterom R
Neuroendocrinology; 1982; 34(5):339-42. PubMed ID: 7078703
[TBL] [Abstract][Full Text] [Related]
28. The medical treatment of the hypersecreting pituitary gland.
Corenblum B
Can J Neurol Sci; 1985 Aug; 12(3):243-50. PubMed ID: 2996735
[TBL] [Abstract][Full Text] [Related]
29. Demonstration of specific dopamine receptors on human pituitary adenomas.
Koga M; Nakao H; Arao M; Sato B; Noma K; Morimoto Y; Kishimoto S; Mori S; Uozumi T
Acta Endocrinol (Copenh); 1987 Apr; 114(4):595-602. PubMed ID: 3577589
[TBL] [Abstract][Full Text] [Related]
30. Interactions between thioridazine and bromocriptine in a patient with a prolactin-secreting pituitary adenoma.
Robbins RJ; Kern PA; Thompson TL
Am J Med; 1984 May; 76(5):921-3. PubMed ID: 6720732
[TBL] [Abstract][Full Text] [Related]
31. Regression of a prolactin-secreting pituitary tumor during long-term treatment with bromocriptine.
Nillius SJ; Bergh T; Lundberg PO; Stahle J; Wide L
Fertil Steril; 1978 Dec; 30(6):710-2. PubMed ID: 729834
[TBL] [Abstract][Full Text] [Related]
32. Clinical and pathological effects of bromocriptine on prolactin-secreting and other pituitary tumors.
Barrow DL; Tindall GT; Kovacs K; Thorner MO; Horvath E; Hoffman JC
J Neurosurg; 1984 Jan; 60(1):1-7. PubMed ID: 6689702
[TBL] [Abstract][Full Text] [Related]
33. Bromocriptine-induced changes in hormone secretion and cell morphology in growth hormone and prolactin producing pituitary adenomas.
Anniko M; Werner S; Wersäll J
Acta Otolaryngol; 1981; 92(3-4):343-55. PubMed ID: 7324902
[No Abstract] [Full Text] [Related]
34. Effect of dopamine agonist medication on prolactin producing pituitary adenomas. A morphological study including immunocytochemistry, electron microscopy and in situ hybridization.
Kovacs K; Stefaneanu L; Horvath E; Lloyd RV; Lancranjan I; Buchfelder M; Fahlbusch R
Virchows Arch A Pathol Anat Histopathol; 1991; 418(5):439-46. PubMed ID: 2035258
[TBL] [Abstract][Full Text] [Related]
35. Persisting suppression of prolactin secretion after long-term treatment with bromocriptine in patients with prolactinomas.
Eversmann T; Fahlbusch R; Rjosk HK; von Werder K
Acta Endocrinol (Copenh); 1979 Nov; 92(3):413-27. PubMed ID: 574700
[TBL] [Abstract][Full Text] [Related]
36. Positron emission tomography in acromegaly and other pituitary adenoma patients.
Muhr C
Neuroendocrinology; 2006; 83(3-4):205-10. PubMed ID: 17047384
[TBL] [Abstract][Full Text] [Related]
37. [Clinical application of 11C-NMSP to the patients with pituitary adenoma other than prolactinoma].
Momose T; Teramoto A; Nishikawa J; Inoue Y; Watanabe T; Sasaki Y
Kaku Igaku; 1993 Jun; 30(6):627-35. PubMed ID: 8345693
[TBL] [Abstract][Full Text] [Related]
38. Differentiation of pituitary adenoma and meningioma: visualization with positron emission tomography and [11C]-L-deprenyl.
Bergström M; Muhr C; Jossan S; Lilja A; Nyberg G; Långström B
Neurosurgery; 1992 Jun; 30(6):855-61. PubMed ID: 1614586
[TBL] [Abstract][Full Text] [Related]
39. Size reduction of a prolactin secreting adenoma during long-term treatment with the dopamine agonist lisuride.
Chiodini PG; Liuzzi A; Verde G; Cozzi R; Silvestrini F; Marsili MT; Horowski R; Passerini F; Luccarelli G; Borghi PG
Clin Endocrinol (Oxf); 1980 Jan; 12(1):47-51. PubMed ID: 7379313
[TBL] [Abstract][Full Text] [Related]
40. [Medical treatment of prolactin-secreting pituitary adenomas. Influence of the size of the adenoma].
Kuhn JM; Gancel A; Weinstein A; Courtois H; Schrub JC; Tadie M; Wolf LM
Presse Med; 1985 Mar; 14(9):525-8. PubMed ID: 3157164
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
